Michael A. Metzger, chief executive officer of Syndax Pharmaceuticals Inc (NASDAQ:SNDX), recorded an open-market sale of 7,412 shares on February 6, 2026. The transaction was executed at $20.62 per share and amounted to $152,835 in total proceeds.
Syndax's equity has enjoyed considerable appreciation recently, with the stock up approximately 63% over the prior six months and trading at about $21.01 at the time of the transaction. InvestingPro data cited in company disclosures indicates that Syndax appears slightly undervalued when measured against the platform's Fair Value assessment.
The filings detail additional equity activity earlier in the week. On February 4, 2026, Metzger was recorded as acquiring two grants of common stock at no cost - one for 73,000 shares and another for 144,600 shares. That same day he received an award of 440,000 stock options with an exercise price of $20.43.
After accounting for the sale and the awards, Metzger directly holds 508,849 shares of Syndax common stock. The company carries a market capitalization of approximately $1.84 billion and has its next scheduled earnings release on March 9, 2026.
Investment research captured in the disclosures notes a mixed operational picture. While analyst coverage includes price targets that range from $27 to $56 and several firms have raised earnings estimates, InvestingPro also highlights that Syndax is rapidly consuming cash and is not projected to be profitable during the current year.
Separately, Syndax has been notable for recent clinical and commercial developments. The company presented data at the 67th American Society of Hematology Annual Meeting for its FDA-approved menin inhibitor, Revuforj. The results reported a 77% overall response rate among relapsed or refractory acute leukemia patients, with 75% of responders achieving measurable residual disease negativity.
Those clinical disclosures coincided with multiple sell-side firms reiterating favorable coverage. B.Riley reiterated its Buy rating and set a $33.00 price target, calling out approximately $1.4 million in early-2026 sales for the partnered therapy Niktimvo. H.C. Wainwright kept its Buy rating and a $40.00 target, highlighting the therapy's performance in routine care settings. TD Cowen also maintained a Buy rating following the company’s visibility at the ASH meeting.
Taken together, the regulatory-approved trial data and reiterated analyst endorsements form the public record around Syndax’s recent momentum. At the same time, the company’s financial profile as described by InvestingPro points to cash-burn and short-term unprofitability risks that market participants will likely monitor as the company moves toward its next reported quarter on March 9, 2026.
Note on coverage: This article presents a factual account of reported insider transactions, recent clinical data releases, analyst actions, and financial commentary as disclosed in company filings and research summaries.